Ethicor Pharma Ltd


Press release   •   May 15, 2012 05:03 EDT



Steve Parkinson

President and CEO

Lakewood-Amedex Inc.

1-941 225 2515

Richard Drury

Managing Director

Ethicor Pharma Ltd.

44-1352 759714


Sarasota, Florida and London, UK, May 15, 2012 – Lakewood-Amedex Inc., (L-A), a leading developer of novel anti-infective pharmaceuticals, and Ethicor Pharma Ltd, a company engaged in the specialty pharmaceutical sector in the European medical community announced today that they have entered into an agreement under which Ethicor and Lakewood-Amedex will collaborate in the development of Nu-2 topical anti-microbial-bacterial product in Europe, South America, Australasia and the Middle East for the treatment of infected diabetic ulcers that have failed to respond to standard of care therapies.

NuBiotics are a new class of synthetic broad spectrum anti-microbial compounds that have been proven effective against all strains of bacteria and fungi tested to date, including antibiotic resistant strains. These compounds function through a novel mechanism of action resulting in the rapid killing of bacteria and represent a new paradigm in the fight against the rising threat of antibiotic resistant bacteria such as Acinetobacter, Mycobacterium, Pseudomonas, and Staphylococcus. Lakewood- Amedex is developing Nu-2 as a topical product for the treatment of diabetic ulcers, burn wounds, and onychomycosis and Nu-3 as an intravenous product for complicated urinary tract infections.

Lakewood-Amedex’s President and CEO, Steve Parkinson, commented "We are very excited about this collaboration with Ethicor. While this is a new company, the senior executives are very experienced in the pharmaceutical market. Our ultimate aim is to get these products into the hands of clinicians who can use them to help patients who might otherwise lose a limb to untreatable infections."

Richard Drury, Managing Director of Ethicor commented "We were greatly impressed when first introduced to the Lakewood-Amedex product portfolio and the quality of the company’s science. We felt immediately that Nu-2 topical was an ideal product for the Ethicor portfolio. We are building a solid portfolio in our company and a patent-protected first-in-class novel anti-bacterial that can treat a host of topical wounds that have shown to be non-responsive to conventional antibiotics is a great addition to our product offerings. We have identified additional exciting products in the Lakewood-Amedex portfolio that would be well suited to the Ethicor business model and we hope to add more of these to our collaboration in the future, as well as expanding into additional territories."

About Lakewood-Amedex, Inc.

Lakewood-Amedex is a privately held biopharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class anti-bacterial compounds, orally available nanoRNA therapeutics for acute and chronic diseases such as arthritis, inflammation, cancer, influenza, and hepatitis, and a fully human monoclonal antibody for HUS. The Company’s products and technology are covered by an extensive patent portfolio consisting of 36 granted and/or issued patents and 27 pending patent applications covering all major pharmaceutical markets. The Company’s lead therapeutic candidate is a novel synthetic broad spectrum anti-bacterial proven to be effective in killing a wide range of gram positive, gram negative, and antibiotic-resistant bacteria and is expected to enter initial clinical trials in 2012.

About Ethicor Pharma Ltd.

Ethicor Pharma is a newly formed company established for the purpose of bringing to market medicines which address un-met clinical needs in Europe and additional territories. Ethicor will also address the European ‘Specials’ markets which represents a $6 billion per year opportunity. Ethicor has assembled a portfolio of some 40 ‘Specials’ products including novel compounds and unlicensed formulations of generic drugs.

This press release contains forward-looking statements that can be identified by terminology such as "expects", "potential", "suggests", "may", "will" or similar expressions. Such forward-looking statements regarding our business, which are not historical facts, are "forward-looking statements" that involve risk and uncertainties, which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company's planned operations, risk associated with inherent uncertainty of product research and development, risk of protecting proprietary rights and competition. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.